Table 2.

Baseline characteristics of TCGA-LIHC patients

Clinical features	Number (%)	Clinical features	Number (%)
Follow-up time (months)	26.7 ± 23.9	AJCC stage
Survival status		Stage I	170 (46.6%)
Alive	235 (64.4%)	Stage II	84 (23.0%)
Dead	130 (35.6%)	Stage III	83 (22.7%)
Age	59.7 ± 13.4	Stage IV	4 (1.1%)
Sex		Not applicable	24 (6.6%)
Male	246 (67.4%)	T classification
Female	119 (32.6%)	T1	180 (49.3%)
History of other malignancy		T2	91 (24.9%)
No	331 (90.7%)	T3	78 (21.4%)
Yes	34 (9.3%)	T4	13 (3.6%)
History of neoadjuvant treatment		TX	1 (0.3%)
No	363 (99.5%)	Not applicable	2 (0.5%)
Yes	2 (0.5%)	N classification
History of radiation treatment		N0	248 (67.9%)
No	238 (65.2%)	N1	4 (1.1%)
Yes	4 (1.1%)	NX	112 (30.7%)
Not applicable	123 (33.7%)	Not applicable	1 (0.3%)
History of chemotherapy		M classification
No	222 (60.8%)	M0	263 (72.1%)
Yes	14 (3.8%)	M1	3 (0.8%)
Not applicable	129 (35.3%)	MX	99 (27.1%)
History of ablation embolization		Grade
No	230 (63.0%)	G1	55 (15.1%)
Yes	13 (3.6%)	G2	175 (47.9%)
Not applicable	122 (33.4%)	G3	118 (32.3%)
History of hepatic carcinoma risk factory		G4	12 (3.3%)
No history of primary risk factors	91 (24.9%)	Not applicable	5 (1.4%)
Alcohol consumption	115 (31.5%)	Vascular invasion
Hepatitis B	102 (27.9%)	No	205 (56.2%)
Hepatitis C	55 (15.1%)	Micro	90 (24.7%)
Non-alcoholic fatty liver disease	19 (5.2%)	Macro	16 (4.4%)
Hemochromatosis	6 (1.6%)	Not applicable	54 (14.8%)
Other	30 (8.2%)	Relapse
Not available	18 (4.9%)	No	172 (47.1%)
Residual tumor		Yes	94 (25.8%)
RO	320 (87.7%)	Not applicable	99 (27.1%)
R1	17 (4.7%)	Histological diagnosis
R2	1 (0.3%)	Hepatocellular carcinoma	355 (97.3%)
RX	20 (5.5%)	Fibrolamellar carcinoma	3 (0.8%)
Not applicable	7 (1.9%)	Hepatocholangiocarcinoma	7 (1.9%)